Plain-English translation of NCT06829719 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
After a kidney transplant, you take medications to prevent your body from rejecting the new kidney. This study tests whether doctors can use a simple blood test that measures a harmless virus called TTV to figure out the right dose of your medications for you personally. The goal is to prevent long-term problems like infections, cancer, rejection, and graft failure by keeping your immune system at just the right level.
Kidney transplants face serious challenges over time, including infections, cancer, and rejection. Right now, doctors don't have a good way to know if your medication dose is too high, too low, or just right after the first year. This study is trying to solve that problem by using a simple blood marker to guide treatment.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups. Both groups will have blood tests every 6 months for 3 years to measure the TTV virus. If you are in the TTV-guided group, your doctors will use these results to adjust your medication doses to keep the virus level in a target range. If you are in the standard care group, your doctors will continue managing your medications the usual way, and the blood test results won't be shared with them. You'll visit your transplant center regularly as usual, and your doctors will monitor your kidney function with standard blood tests.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
France